Gabapentin Capsule
Product Images NDC 63629-8484

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63629-8484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The horizontal axis shows weeks from baseline to 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The vertical axis measures mean pain score from 0 to 10. Gabapentin group scores decrease steadily while placebo group scores remain relatively stable.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over 7 weeks comparing placebo and two dosages of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks from baseline through weeks 1 to 7, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin treatments show a greater reduction in mean pain scores compared to placebo over time.*

FDA Label Image

Figure 3 (Image 03)

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing Study 1 and Study 2 results. The vertical axis shows percentage responders from 0% to 100%. Study 1 compares placebo (12%) and Gabapentin 3600 mg (29%). Study 2 compares placebo (14%), Gabapentin 1800 mg (32%), and Gabapentin 2400 mg (34%). Statistical significance markers indicate p < 0.01 and p < 0.001 for Gabapentin groups versus placebo.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

A formula illustrating the calculation of creatinine clearance (CLCr) involving variables such as age, weight, serum creatinine, and a gender adjustment factor for females. This formula is commonly used to estimate kidney function.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure diagram showing the molecular formula of Gabapentin, with labeled substituents including a cyclohexane ring, primary amine, and carboxylic acid groups.*

FDA Label Image

Image-09 (Image 09)

A scatter plot comparing percentage differences across daily doses (600 mg, 900 mg, 1200 mg, 1800 mg) in three studies labeled a, b, and c. The vertical axis represents the difference in percentage, while the horizontal axis shows the daily dose in milligrams. Each study is represented by a distinct marker and color.*

FDA Label Image

Label (Lbl636298484)

Gabapentin Capsules, USP 100 mg oral dosage form packaging label showing the NDC 63629-8484-1. The label includes storage instructions, manufacturer Silexgen Pharmaceuticals Inc., relabeled by Bryant Ranch Prepack, and container details. The package count is 500 capsules with BRP Pharmaceuticals logo and indication for Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.